QLF4113 in Participants With Metastatic Prostate Cancer
2026年6月4日 更新者：Qilu Pharmaceutical Co., Ltd.
An Open-label, Multicenter Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of QLF4113 for Injection in Participants With Metastatic Prostate Cancer.
This is an open-label, dose-escalation and expansion Phase I clinical trial designed to evaluate the safety, tolerability, pharmacokinetic (PK) profile, immunogenicity, and preliminary antitumor activity of QLF4113 monotherapy in participants with metastatic prostate cancer.
The Phase I trial consists of two parts: Phase Ia and Phase Ib. Phase Ia is a dose-escalation study of QLF4113 monotherapy to determine the recommended phase two dose and assess safety and PK. Then the study will proceed to Phase Ib, a dose-expansion study to further evaluate the preliminary efficacy and safety of QLF4113 monotherapy under the selected doses.
研究概览
研究类型
介入性
注册 (估计的)
140
阶段
- 阶段1
联系人和位置
本节提供了进行研究的人员的详细联系信息，以及有关进行该研究的地点的信息。
学习联系方式
- 姓名：Jun Guo, Doctor
- 电话号码：0086-10- 88121122
- 邮箱：guoj307@126.com
参与标准
研究人员寻找符合特定描述的人，称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
不
描述
Inclusion Criteria:
- Participants voluntarily agree to participate and sign the informed consent form.
- Male, aged ≥18 years.
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1.
- Life expectancy ≥ 3 months.
- Histologically or cytologically confirmed adenocarcinoma of the prostate without evidence of neuroendocrine carcinoma or small cell carcinoma features.
- Confirmed metastatic Castration-Resistant Prostate Cancer (mCRPC).
- Failed or are intolerant to standard therapies
- Adequate function of major organs as defined by the protocol.
- Agreement to use effective contraception during the study (except for subjects who have undergone bilateral orchiectomy).
- Prior to the first use of the investigational drug, recovery from all reversible adverse events (AEs) related to prior anticancer treatments
Exclusion Criteria:
- Previously treated with drugs targeting CD3 or CD2.
- Significant Cardiovascular Diseases
- Active, Uncontrolled Infections
- Immunosuppressive Treatment before the first dose of the investigational drug
- Clinically Uncontrolled Third-Space Fluid Accumulation
- History of Other Malignancies within 5 years prior to the first dose of the investigational drug
- Moderate to Severe Pulmonary Diseases significantly affecting lung function,
- Current Hepatic Encephalopathy, Hepatorenal Syndrome, or Cirrhosis classified as Child-Pugh B or worse.
- Allergy to the Investigational Drug or its Components.
- Any Condition deemed by the investigator to increase study-related risks, interfere with the interpretation of study results, or otherwise render the participant unsuitable for inclusion.
学习计划
本节提供研究计划的详细信息，包括研究的设计方式和研究的衡量标准。
研究是如何设计的？
设计细节
- 主要用途：治疗
- 分配：不适用
- 介入模型：单组作业
- 屏蔽：无（打开标签）
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的：QLF4113 dose escalation arm
|
A PSMA/CD3/CD2 antibody
|
研究衡量的是什么？
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Maximum tolerated dose (MTD) (Phase Ia)
大体时间：From first dose of study treatment until the end of Cycle 1 (21 days)
|
Maximum tolerated dose is defined as the previous dose level at which 2 or more out of 2-6 participants experienced a dose-limited toxicity (DLT).
|
From first dose of study treatment until the end of Cycle 1 (21 days)
|
|
Maximum administered dose (MAD)(Phase Ia)
大体时间：From first dose of study treatment until the end of Cycle 1 (21 days)
|
MAD is defined as follows: a) based on PK data, it is anticipated that at this dose level, the dose-exposure plateau has been reached, b) based on existing safety data, it is judged that dose escalation following this dose level will have a large safety risk or subject intolerance, or c) based on the PK-PD model, it suggested that the optimal target concentration of safety and efficacy has been explored.
|
From first dose of study treatment until the end of Cycle 1 (21 days)
|
|
recommended phase II dose (RP2D)
大体时间：Through phase Ia completion, approximately 1 year.
|
The RP2D will be comprehensively evaluated based on the safety, PK characteristics, and efficacy data from the Phase Ia study.
|
Through phase Ia completion, approximately 1 year.
|
|
The incidence and severity of adverse events (AE) (Phase Ib)
大体时间：Through phase Ia completion, approximately 1 year.
|
Incidence and severity of adverse events (AEs) evaluated according to the National Cancer Institute (NCI)-Common Terminology Criteria for Adverse Events (CTCA) Version 6.0 (v6.0) and American Society for Transplantation and Cellular Therapy (ASTCT)
|
Through phase Ia completion, approximately 1 year.
|
|
PSA50 response (Phase Ib)
大体时间：From Screening to confirmed progressive disease (approximately 1 year)
|
Best response until progression, as defined by Response Evaluation Criteria in Solid Tumors （RECIST） version (v1.1) and Prostate Cancer Clinical Trials Working Group 3 (PCGW3).
|
From Screening to confirmed progressive disease (approximately 1 year)
|
|
Objective response rate (ORR) (phase Ib)
大体时间：From Screening to confirmed progressive disease (approximately 1 year)
|
From Screening to confirmed progressive disease (approximately 1 year)
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查，以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (估计的)
2026年7月20日
初级完成 (估计的)
2028年1月5日
研究完成 (估计的)
2028年12月5日
研究注册日期
首次提交
2026年6月4日
首先提交符合 QC 标准的
2026年6月4日
首次发布 (实际的)
2026年6月9日
研究记录更新
最后更新发布 (实际的)
2026年6月9日
上次提交的符合 QC 标准的更新
2026年6月4日
最后验证
2026年6月1日
更多信息
此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.